Group 1 - The core viewpoint of the news is that Diweier's stock has experienced a decline in price and trading activity, with a notable drop in both share price and market capitalization [1][2] - As of January 8, Diweier's stock price was 35.83 yuan per share, with a total market capitalization of 6.975 billion yuan [1] - The company has seen a year-to-date stock price decrease of 2.37%, with a 5-day decline of 2.13% and a 20-day decline of 5.26% [2] Group 2 - Diweier reported a revenue of 873 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 9.86% [2] - The net profit attributable to shareholders for the same period was approximately 89.71 million yuan, showing a significant increase of 40.59% year-on-year [2] - The company has distributed a total of 134 million yuan in dividends since its A-share listing, with 103 million yuan distributed over the past three years [3] Group 3 - As of September 30, 2025, Diweier had 4,884 shareholders, an increase of 8.53% from the previous period, while the average circulating shares per person decreased by 7.86% to 39,858 shares [2] - Among the top ten circulating shareholders, Noan Pioneer Mixed A holds 8.79 million shares, remaining unchanged, while Fortune Tianhui Growth Mixed A/B increased its holdings by 253,000 shares [3]

获得上海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京迪威尔高端制造股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日收 到上海证券交易所（以下简称"上交所"）出具的《关于受理南京迪威尔高端制造股份 有限公司科创板上市公司发行证券申请的通知》（上证科审（再融资）〔2025〕187 号）， 上交所对公司报送的科创板上市公司发行证券的募集说明书及相关申请文件进行了核 对，认为该项申请文件齐备，符合法定形式，决定予以受理并依法进行审核。 公司本次向不特定对象发行可转换公司债券事项尚需通过上交所审核，并获得中 国证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施。 最终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不确定 性。公司将根据该事项的进展情况，按照相关规定和要求及时履行信息披露义务，敬 请广大投资者注意投资风险。 特此公告。 证券代码：688377 证券简称：迪威尔 公告编号：2025-038 南京迪威尔高端制造股份有限公司 关于向不特 ...

Group 1 - The core technical personnel, Mr. Chen Changhua, has resigned from Nanjing Diwei High-end Manufacturing Co., Ltd. due to personal reasons and will no longer hold any position in the company [2][3] - The company has signed a confidentiality and non-compete agreement with Mr. Chen, ensuring no disputes regarding job inventions and that the company's patent rights remain intact [2][5] - The work previously handled by Mr. Chen has been successfully transitioned to other personnel within the department, and his departure will not materially affect the company's technological research and core competitiveness [2][8] Group 2 - Mr. Chen, a senior engineer and a key figure in the company's research and development, has contributed significantly to the company since joining in April 2012 [4][3] - The company has a stable research and development team, with the number of R&D personnel increasing from 128 in 2022 to 149 in 2024, maintaining a strong talent base for continuous innovation [7][8] - The company emphasizes the cultivation of technical talent and has established a mature R&D team led by core technical personnel, ensuring ongoing support for future technological advancements [7][8] Group 3 - The company has taken measures to ensure that all ongoing R&D projects are progressing normally and that the core technical team can support future research and development efforts [8] - The company plans to further enhance its technical innovation capabilities by increasing the recruitment and training of professional technical personnel [8]

Core Viewpoint - The company announced the resignation of its core technical personnel, Mr. Chen Changhua, who was re-employed after reaching the legal retirement age in May 2023, and has now completed the resignation process and will no longer hold any position in the company [2]. Group 1 - Mr. Chen Changhua reached the legal retirement age in May 2023 [2] - He was re-employed by the company after reaching retirement age [2] - Mr. Chen has applied for resignation due to personal reasons and has completed the departure process [2]

Core Viewpoint - The company announced adjustments to its 2021 restricted stock incentive plan, including changes to the grant price and the conditions for the third vesting period [2]. Group 1 - The sixth board of directors of the company approved the proposal to adjust the grant price of the 2021 restricted stock incentive plan [2]. - The board also approved the achievement conditions for the first and reserved portions of the third vesting period of the 2021 restricted stock incentive plan [2].

Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]

Group 1 - The company, Diwei'er, announced that its sixth board meeting will be held on December 19, 2025, to review the proposal for adjusting the grant price of the 2021 restricted stock incentive plan [1] - For the year 2024, the company's revenue composition is as follows: 95.19% from the oil and gas industry, 3.53% from other businesses, and 1.29% from other sources [1] - As of the time of reporting, Diwei'er has a market capitalization of 6.8 billion yuan [1]

关于调整 2021 年限制性股票激励计划授予价格的公告 证券代码：688377 证券简称：迪威尔 公告编号：2025-034 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京迪威尔高端制造股份有限公司 南京迪威尔高端制造股份有限公司（以下简称 "公司"）于2025年12月19日召开 第六届董事会第十次会议，审议通过了《关于调整2021年限制性股票激励计划授予 价格的议案》。根据公司《2021年限制性股票激励计划（草案）》（以下简称《激 励计划》）的有关规定及公司2022年第一次临时股东大会的授权，董事会对本激励 计划的授予价格（含预留授予）进行了调整，现将有关事项说明如下： 一、2021 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2021 年 11 月 26 日，公司召开第五届董事会第三次会议，会议审议通过了 《关于<南京迪威尔高端制造股份有限公司 2021 年限制性股票激励计划（草案） > 及其摘要的议案》《关于<南京迪威尔高端制造股份有限公司 2021 年限制性股票激 励计划实施考核管理办法>的议案》 ...

法律意见书 北京国枫律师事务所 关于南京迪威尔高端制造股份有限公司 2021 年限制性股票激励计划授予价格调整、首次及 预留部分第三个归属期归属条件成就的 国枫律证字|2024|AN152-2 号 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel） 010-88004488/66090088 传真(Fax): 010-66090016 北京国枫律师事务所 关于南京迪威尔高端制造股份有限公司 2021年限制性股票激励计划授予价格调整、首次及 预留部分第三个归属期归属条件成就的 法律意见书 对本法律意见书的出具,本所律师特作如下声明: 1. 本所及经办律师依据《公司法》《证券法》《管理办法》《业务管理办 法》等规定及本法律意见书出具目以前已经发生或者存在的事实,严格履行了法 定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证法律意 见所认定的事实真实、准确、完整,所发表的结论性意见合法、准确,不存在虚 假记载、误导性陈述或者重大遗漏,并承担相应法律责任; 2. 本所律师同意将 ...

证券代码：688377 证券简称：迪威尔 公告编号：2025-037 南京迪威尔高端制造股份有限公司 关于公司核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京迪威尔高端制造股份有限公司（以下简称"公司"）核心技术人员陈昌华 先生因个人原因向公司申请不再继续返聘并于近日办理完毕离职手续。离职后，陈昌 华先生不再担任公司任何职务。 公司与陈昌华先生签署了保密及竞业限制协议，不存在涉及职务发明的纠纷或 潜在纠纷，也不会影响公司专利权的完整。 经公司研究决定，陈昌华先生离职后，其负责的工作由该部门其他人员接任， 并已完成工作交接。陈昌华先生的离职不会对公司技术研发、核心竞争力及持续经营 能力产生实质性影响。 一、 核心技术人员离职的具体情况 公司核心技术人员陈昌华先生于 2023 年 5 月达到法定退休年龄后继续被公司返聘， 其因个人原因于近日向公司申请不再继续返聘并已办理完成离职手续，离职后不再担 任公司任何职务。公司及董事会对陈昌华先生任职期间为公司发展所做出的努力和贡 献表示衷心感 ...